Drugs / Human tetanus immunoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07149454 | Aug 2025 → May 2026 overdue | tetanus | Lanzhou Institute of Biological Products Co., Ltd | Enrolling by invitation | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07633119 Comparator | Jun 2026 → Mar 2027 expected | tetanus | Sinovac Life Sciences Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05664750 Comparator | Dec 2022 → Mar 2023 | tetanus | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human tetanus immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664750 ↗ |
| Known as | HTIG | “plasma-derived human tetanus immunoglobulin (HTIG)” PMID 40628965 ↗ Jul 20252“human tetanus immunoglobulin (HTIG) injection” NCT07149454 ↗ “Human tetanus immunoglobulin (HTIG)” NCT07633119 ↗ |
| Modality | Protein / enzyme biologic | “plasma-derived human tetanus immunoglobulin (HTIG)” PMID 40628965 ↗ Jul 2025 |
| Route | Intramuscular | “intramuscular injection” NCT07149454 ↗ |